AEON Biopharma Files Definitive Proxy Statement

Ticker: AEON · Form: DEF 14A · Filed: Jan 23, 2025 · CIK: 1837607

Sentiment: neutral

Topics: proxy-statement, annual-meeting, governance

Related Tickers: AEON

TL;DR

AEON Biopharma's proxy statement is out for the Feb 24 meeting - vote on exec pay & board!

AI Summary

AEON Biopharma, Inc. filed its definitive proxy statement on January 23, 2025, for its annual meeting on February 24, 2025. The company, formerly known as Priveterra Acquisition Corp. until December 22, 2020, is seeking shareholder approval for matters related to its corporate governance and operations. The filing details executive compensation, board nominations, and other shareholder proposals.

Why It Matters

This filing provides shareholders with crucial information regarding upcoming votes on company leadership and strategic decisions, impacting the future direction and governance of AEON Biopharma.

Risk Assessment

Risk Level: low — This is a routine proxy filing, providing information to shareholders for an upcoming meeting, and does not inherently introduce new financial or operational risks.

Key Players & Entities

FAQ

What is the purpose of this DEF 14A filing?

The purpose of this DEF 14A filing is to provide shareholders with a definitive proxy statement for AEON Biopharma, Inc.'s upcoming annual meeting on February 24, 2025, detailing matters for shareholder vote.

When was AEON Biopharma, Inc. formerly known as?

AEON Biopharma, Inc. was formerly known as Priveterra Acquisition Corp. until December 22, 2020.

What is the filing date of this proxy statement?

This definitive proxy statement was filed on January 23, 2025.

What is the scheduled date for the shareholder meeting?

The shareholder meeting is scheduled for February 24, 2025.

What type of SEC filing is this?

This is a DEF 14A filing, which is a Definitive Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Filing Stats: 4,746 words · 19 min read · ~16 pages · Grade level 15.5 · Accepted 2025-01-23 16:45:44

Key Financial Figures

Filing Documents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 19 WHERE YOU CAN FIND MORE INFORMATION ABOUT AEON BIPOHARMA, INC. 21 OTHER MATTERS 22 Table of Contents 5 Park Plaza, Suite 1750 Irvine, CA 92614 (949) 354-6499 PROXY STATEMENT FOR SPECIAL MEETING OF STOCKHOLDERS FEBRUARY 24, 2025 This proxy statement contains information related to a Special Meeting of Stockholders of AEON Biopharma, Inc. which will be held at 10:00 a.m. Pacific Time, at 5 Park Plaza, Suite 1750, Irvine, California 92614 on Monday, February 24, 2025, and any postponements or adjournments of the meeting. We first mailed these proxy materials to stockholders on or about January 23, 2025. In this proxy statement, "Company," "AEON," "we," "us," and "our" each refer to AEON Biopharma, Inc. and its subsidiaries. ABOUT THE PROXY MATERIALS We are furnishing proxy materials to our stockholders of record on January 7, 2025, in connection with the solicitation of proxies by our Board of Directors (the "Board") for use at a Special Meeting of stockholders to be held at 10:00 a.m. Pacific Time, at 5 Park Plaza, Suite 1750, Irvine, California 92614 on Monday, February 24, 2025. This proxy is being solicited by the Board, and the cost of solicitation of the proxies will be paid by AEON. Our officers, directors and regular employees, without additional compensation, also may solicit proxies by further mailing, by telephone or personal conversations. We have no plans to retain any firms or otherwise incur any extraordinary expense in connection with the solicitation. IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON FEBRUARY 24, 2025 This Proxy Statement, and the enclosed proxy card, are available at www.proxyvote.com. Stockholder of Record: Shares Registered in Your Name If you are a stockholder of record, you may vote using the following methods: At the Special Meeting. To vote at the Special M

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing